Financing ·
REGENXBIO Inc. entered into an underwriting agreement on July 16, 2026, to offer and sale of 10,003,889 shares of…
RGNXREGENXBIO Inc.
REGENXBIO Inc. entered into an underwriting agreement on July 16, 2026, to offer and sale of 10,003,889 shares of common stock at $9.00 per share and 1,111,111 pre-funded warrants at $8.9999 per warrant. The underwriters, including Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, Leerink Partners LLC and Mizuho Securities USA LLC, as representatives, exercised an option to purchase an additional 1,667,250 shares of common stock. The net proceeds from the offering, including the exercise of the option, are expected to be approximately $107.8 million. REGENXBIO is a biotechnology company focused on gene therapy development for rare and retinal diseases.